Central Retinal Artery Occlusion: Local Intra-arterial Fibrinolysis versus Conservative Treatment, a Multicenter Randomized Trial

医学 视网膜中央动脉阻塞 随机对照试验 视力 眼科 纤溶 不利影响 外科 内科学
作者
Martin Schumacher,Nicole Eter,Bernhard Jurklies,Christine Gall,Isabel Wanke,Claudia Schmoor,H. Maier-Lenz,L. Solymosi,Hartmut Brueckmann,Aljoscha S. Neubauer,Armin Wolf,Nicolas Feltgen
出处
期刊:Ophthalmology [Elsevier BV]
卷期号:117 (7): 1367-1375.e1 被引量:281
标识
DOI:10.1016/j.ophtha.2010.03.061
摘要

Purpose The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Design Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Participants Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Methods Patients (age 18–75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) <0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. Main Outcome Measures The primary end point was BCVA after 1 month; the secondary end point was safety. Results The mean interval between first symptoms and therapy was 10.99±5.49 hours (CST) and 12.78±5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: −0.44 [standard deviation 0.55]; LIF: −0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (≥0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. Conclusions In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Patients (age 18–75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) <0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. The primary end point was BCVA after 1 month; the secondary end point was safety. The mean interval between first symptoms and therapy was 10.99±5.49 hours (CST) and 12.78±5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: −0.44 [standard deviation 0.55]; LIF: −0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (≥0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
KK完成签到,获得积分10
1秒前
careyzhou发布了新的文献求助10
2秒前
中原第一深情完成签到,获得积分10
2秒前
小洪俊熙发布了新的文献求助10
3秒前
北望完成签到,获得积分20
3秒前
Lee完成签到 ,获得积分10
4秒前
科研狗完成签到 ,获得积分10
5秒前
量子星尘发布了新的文献求助10
7秒前
7秒前
romeo发布了新的文献求助10
10秒前
妖孽宇完成签到,获得积分10
12秒前
简简单单完成签到,获得积分10
12秒前
550190946发布了新的文献求助10
12秒前
14秒前
111完成签到,获得积分10
14秒前
zhubin完成签到 ,获得积分10
14秒前
16秒前
田南松发布了新的文献求助10
19秒前
搬砖美少女完成签到,获得积分10
19秒前
nn发布了新的文献求助10
20秒前
7ohnny完成签到,获得积分10
21秒前
apckkk完成签到 ,获得积分10
23秒前
深情安青应助550190946采纳,获得10
24秒前
25秒前
26秒前
jbq完成签到 ,获得积分20
26秒前
YM完成签到,获得积分10
28秒前
生动柔发布了新的文献求助10
28秒前
大旭完成签到 ,获得积分10
29秒前
Fn完成签到 ,获得积分10
31秒前
zero完成签到,获得积分10
33秒前
瘦瘦谷兰完成签到,获得积分10
33秒前
zcz完成签到 ,获得积分10
34秒前
白嘉乐完成签到,获得积分10
35秒前
考研小白完成签到,获得积分10
35秒前
高妍纯完成签到 ,获得积分10
37秒前
39秒前
风中的丝袜完成签到,获得积分10
39秒前
赵赵完成签到,获得积分10
42秒前
42秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022